Latest From Genaera Corp.
As NIH workshop discusses novel approaches to combatting antibiotic resistance from monoclonal antibodies to synthetic stool transplants and antimicrobial peptides, plans are underway to expand BARDA’s focus beyond biodefense.
The recent acquisition of the shares of Alcon that Novartis didn’t own for about $13 billion might have reinforced investors’ appetite for eye care-related pharmaceuticals (scripintelligence.com, 15 Dec 2010). However, Novartis’ consolidation of Alcon appeared more of a move to wholly own a separate business unit complete with sales force, a dominant position in soup-to-nuts eye care and sales of $6.5bn, than a focus on a particular new drug. On the other hand, Sanofi’s acquisition of the private company Fovea Pharmaceuticals SA (scripintelligence.com, 1 Oct 2009) marked a rare big pharmaceutical foray for an ophthalmology pipeline.
Crunched credit wiped out many biotech firms in 2009, yet some emerged from the wreckage leaner and stronger. How did they do it, asks Dr Sukaina Virji-Jeganathan.
The European regulator's recent decision to suspend sales of Sanofi-Aventis's Acomplia (rimonabant) came hot on the heels of setbacks with two other late-stage CB1 antagonist agents, and the developments have put the spotlight on obesity as a therapy area and made some observers question whether this is still a market potentially worth billions of dollars.
Drug Discovery Tools
- Natural Products
- Molecular Diversity
- Drug Discovery Tools
- Therapeutic Areas
- Magainin Pharmaceuticals Inc.
- North America
- Parent & Subsidiaries
- Genaera Corp.
- Senior Management
John L Armstrong, Jr., Pres. & CEO
Leanne M Kelly, SVP, CFO
Michael J Gast, MD, PhD, EVP, CMO
- Contact Info
Phone: (610) 941-4020
5110 Campus Dr.
Plymouth Meeting, PA 19462
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.